Post by
HighteawithIntrepid on Nov 13, 2014 6:29pm
Cost structure
When a cancer drug is introduced to your blood stream it is not
by Bob and Doug in a wood shed.
It is administered in a hospital by a team of medical specialists.
It is my best guess that our share of the total cost is net of the cost
of administration such that it will cost the patient $3,000 a pop but not all
of that money will flow to us.
BNC stated the best guess number was $150 m for their stated target market.
The 64,000 question is will the medical community look at the results and say
"let's give her a go as first line" or follow the prescribed regime.
there is a 20 fold gap between 10k and 200k
so a best guess of $2 to $20 for our target share price.
until we get approval it is still a coin toss
what I want to see is insider buying so if anyone has
acess to that info please let us know.
it is tough to sit on your hands but until we know
how the FDA review is going your putting your
money on the roulette wheel
For those of us that have doubled down more than once
it is tough to do it one more time.
give it a rest until January
Nice to see the regulars at the AGM.
Welcome Pat
HT
Comment by
Buck$ter on Nov 13, 2014 7:18pm
Thanks HT, and it was good to see Beech tuning up the hierarchy. Hope we all are successful with this stock. I was big time impressed by the good Dr.
Comment by
CasusFortuitus on Nov 14, 2014 10:32am
Somewhat hyper-sensitive, RG. Wow.